The pharmaceutical industry’s ability to evolve alongside innovations in technology and science increases with the incorporation of digital systems and redesigned data collectors. Pharma 4.0™ is a trending industry initiative that highlights the impact and benefit of digitalisation in pharma operations and production. Digitalisation of pharma manufacturing can propel the industry forward and facilitate technological, economical, and logistical advancement.
There are very different perspectives and drivers to Pharma 4.0™ for the different stakeholders:
The 2019 ISPE Europe Pharma 4.0™ Conference is an interactive forum where top business leaders and CEOs of the industry will discuss their strategic plans for the future of pharmaceutical engineering with the implementation of digitalisation.
The two-day event will answer questions like:
Unlike other huge events, you'll have the opportunity to connect directly with knowledgeable presenters representing leading organisations, including FDA, GSK, LifeBee, MHRA, Merck, Siemens UK, Werum IT Solutions, and more.
Register today for the 2019 ISPE Europe Pharma 4.0™ Conference to stay on track with the latest evolutions on the Pharma 4.0™ topic to successfully implement strategies for your company. Come early and take advantage of in-depth training on 18–19 November to take a deeper dive into three critical areas of pharma manufacturing.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...